振東製藥(300158.SZ):獲得醋酸阿比特龍的藥品註冊批件
格隆匯3月22日丨振東製藥(300158.SZ)公佈,近日,山西振東製藥股份有限公司收到國家食品藥品監督管理局簽發的《藥品註冊批件》。相關藥品名稱:醋酸阿比特龍片;規格:250mg。
醋酸阿比特龍在體內轉化成阿比特龍,阿比特龍是一種雄激素生物合成抑制劑,可抑制17α-羥化酶/C17,20-裂解酶(CYP17),後者在睾丸、腎上腺和前列腺腫瘤組織中表達並且是雄激素生物合成所必需的。該品與潑尼松或潑尼松龍合用,治療轉移性去勢抵抗性前列腺癌(mCRPC)及新診斷的高危轉移性內分泌治療敏感性前列腺癌(mHSPC),包括未接受過內分泌治療或接受內分泌治療最長不超過3個月。
根據米內網數據顯示,2021年1-6月,我國醋酸阿比特龍醫院終端銷售額為6.6204億元。2021年1-12月,醋酸阿比特龍的藥店終端銷售額為2.3894億元。目前國內醋酸阿比特龍上市的有西安楊森、成都盛迪醫藥、江蘇正大天晴藥業、江西山香藥業、齊魯製藥、印度瑞迪博士實驗室、杭州和澤坤元藥業和振東製藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.